Women with PMOS should get subsidised weight-loss drugs, Australian advocates say

Women with a chronic hormonal condition are increasingly prescribed weight-loss medications like GLP-1 drugs off-label, despite these treatments not being formally approved for their specific use. Advocacy groups argue that patients should have better access to these taxpayer-funded medications, pushing for their inclusion on the national pharmaceutical subsidy scheme. The call comes as demand grows for more tailored solutions for those managing the condition alongside weight-related health challenges. The debate highlights tensions between off-label prescribing practices and formal regulatory approval processes.

With GLP-1s to treat the condition not specifically approved by the TGA, patients are being prescribed them off-labelGet our breaking news email, free app or daily news podcastWomen living with a chronic hormonal condition should have access to taxpayer-funded weight-loss medications, advocates say.The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia (POSAA) is urging for GLP-1 drugs to be approved on the Pharmaceutical Benefits Scheme for people living with the condition. Continue reading...